An Outcomes Comparison of Native Arteriovenous Fistulae, Polytetrafluorethylene Grafts, and Cryopreserved Vein Allografts

Jadlowiec, Caroline C.; Lavallee, Matthew; Mannion, Elizabeth M.; Brown, Matthew G.

doi:10.1016/j.avsg.2015.07.009

Cited by 13 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even when using optimal surgical insertion technique, patency problems appear with the synthetic material, which raises the interest in tissue-engineered vascular grafts (TEVG). The primary patency rate for AVS at 1 year is around 50% 47 and, in some studies, the failure rate increases to 0.8–1.0 events per patient per year. 24 Many HD patients require an exchange of the AVS after 12 months.…”

Section: Avssmentioning

confidence: 99%

Arteriovenous access in hemodialysis: A multidisciplinary perspective for future solutions

et al. 2020

View full text Add to dashboard Cite

In hemodialysis, vascular access is a key issue. The preferred access is an arteriovenous fistula on the non-dominant lower arm. If the natural vessels are insufficient for such access, the insertion of a synthetic vascular graft between artery and vein is an option to construct an arteriovenous shunt for punctures. In emergency situations and especially in elderly with narrow and atherosclerotic vessels, a cuffed double-lumen catheter is placed in a larger vein for chronic use. The latter option constitutes a greater risk for infections while arteriovenous fistula and arteriovenous shunt can fail due to stenosis, thrombosis, or infections. This review will recapitulate the vast and interdisciplinary scenario that characterizes hemodialysis vascular access creation and function, since adequate access management must be based on knowledge of the state of the art and on future perspectives. We also discuss recent developments to improve arteriovenous fistula creation and patency, the blood compatibility of arteriovenous shunt, needs to avoid infections, and potential development of tissue engineering applications in hemodialysis vascular access. The ultimate goal is to spread more knowledge in a critical area of medicine that is importantly affecting medical costs of renal replacement therapies and patients’ quality of life.

show abstract

Section: Avssmentioning

confidence: 99%

Arteriovenous access in hemodialysis: A multidisciplinary perspective for future solutions

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, because of the challenges of immediate availability, immune acceptance, low thrombogenicity, and required tissue mechanics, small-caliber tissue-engineered blood vessels (TEBVs) are still lack wide clinical use . Autologous blood vessels remain the ideal material for small-caliber vascular grafts because of their superior patency . However, autologous grafts have limitations such as poor quality (being excessively thick or thin), harvesting invasiveness, and unavailability (owing to systemic atherosclerosis or the vessels having already been harvested) .…”

Section: Introductionmentioning

confidence: 99%

Decellularized, Heparinized Small-Caliber Tissue-Engineered “Biological Tubes” for Allograft Vascular Grafts

Su,

Xing,

Xiao

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

There remains a lack of small-caliber tissue-engineered blood vessels (TEBVs) with wide clinical use. Biotubes were developed by electrospinning and in-body tissue architecture (iBTA) technology to prepare small-caliber TEBVs with promising applications. Different ratios of hybrid fibers of poly(l-lactic-co-ε-caprolactone) (PLCL) and polyurethane (PU) were obtained by electrospinning, and the electrospun tubes were then implanted subcutaneously in the abdominal area of a rabbit (as an in vivo bioreactor). The biotubes were harvested after 4 weeks. They were then decellularized and cross-linked with heparin. PLCL/PU electrospun vascular tubes, decellularized biotubes (D-biotubes), and heparinized combined decellularized biotubes (H + D-biotubes) underwent carotid artery allograft transplantation in a rabbit model. Vascular ultrasound follow-up and histological observation revealed that the biotubes developed based on electrospinning and iBTA technology, after decellularization and heparinization cross-linking, showed a better patency rate, adequate mechanical properties, and remodeling ability in the rabbit model. IBTA technology caused a higher patency, and the heparinization cross-linking process gave the biotubes stronger mechanical properties.

show abstract

“…In cardiovascular diseases (CVDs), traumatic injury, and end-stage renal diseases (ESRDs), the need for vascular grafts and vascular access is significant and increasing, especially for small-calibre blood vessels (<6 mm). To date, autologous blood vessels are still the ideal material for small-calibre vascular grafts because of their superior patency [ 1 ]. However, autologous grafts still have limitations, such as poor quality (excessively thick or thin), harvesting invasiveness, and unavailability (due to systemic atherosclerosis or the vessels having already been harvested) [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Biological small-calibre tissue engineered blood vessels developed by electrospinning and in-body tissue architecture

Xing

Wang

et al. 2022

J Mater Sci: Mater Med

View full text Add to dashboard Cite

There are no suitable methods to develop the small-calibre tissue-engineered blood vessels (TEBVs) that can be widely used in the clinic. In this study, we developed a new method that combines electrospinning and in-body tissue architecture(iBTA) to develop small-calibre TEBVs. Electrospinning imparted mechanical properties to the TEBVs, and the iBTA imparted biological properties to the TEBVs. The hybrid fibres of PLCL (poly(L-lactic-co-ε-caprolactone) and PU (Polyurethane) were obtained by electrospinning, and the fibre scaffolds were then implanted subcutaneously in the abdominal area of the rabbit (as an in vivo bioreactor). The biotubes were harvested after four weeks. The mechanical properties of the biotubes were most similar to those of the native rabbit aorta. Biotubes and the PLCL/PU vascular scaffolds were implanted into the rabbit carotid artery. The biotube exhibited a better patency rate and certain remodelling ability in the rabbit model, which indicated the potential use of this hybridization method to develop small-calibre TEBVs.

show abstract

An Outcomes Comparison of Native Arteriovenous Fistulae, Polytetrafluorethylene Grafts, and Cryopreserved Vein Allografts

Cited by 13 publications

References 22 publications

Arteriovenous access in hemodialysis: A multidisciplinary perspective for future solutions

Arteriovenous access in hemodialysis: A multidisciplinary perspective for future solutions

Decellularized, Heparinized Small-Caliber Tissue-Engineered “Biological Tubes” for Allograft Vascular Grafts

Biological small-calibre tissue engineered blood vessels developed by electrospinning and in-body tissue architecture

Contact Info

Product

Resources

About